둘바루맙
|
|
둘바루맙 속성
- 저장 조건
- Store at 4°C, do not freeze
- 용해도
- DMSO에 용해됨
- 물리적 상태
- Liquid
- 색상
- Colorless to light yellow
안전
둘바루맙 C화학적 특성, 용도, 생산
용도
Durvalumab is used to treat non-small cell lung cancer (NSCLC) that spread to nearby tissues and cannot be removed by surgery but has not worsened after being treated with other chemotherapy medications and radiation treatments. Durvalumab injection is also used in combination with etoposide (Etopophos) and either carboplatin or cisplatin to treat extensive-stage small cell lung cancer (ES-SCLC) in adults whose cancer has spread throughout the lungs and to other parts of the body.둘바루맙 준비 용품 및 원자재
원자재
준비 용품
둘바루맙 공급 업체
글로벌( 20)공급 업체
| 공급자 | 전화 | 이메일 | 국가 | 제품 수 | 이점 |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354 +1-00000000000 |
marketing@targetmol.com | United States | 19892 | 58 |
| LEAPCHEM CO., LTD. | +86-852-30606658 |
market18@leapchem.com | China | 43348 | 58 |
| SPIRO PHARMA | |
eric_feng1954@126.com | China | 316 | 55 |
| Shanghai EFE Biological Technology Co., Ltd. | 021-65675885 18964387627 |
info@efebio.com | China | 9806 | 58 |
| ShangHai Biochempartner Co.,Ltd | 17754423994 17754423994 |
2853530910@QQ.com | China | 8014 | 62 |
| Fan De(Beijing) Biotechnology Co., Ltd. | 15911056312 |
liming@bio-fount.com | China | 9730 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 |
981810490@qq.com | China | 1565 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 |
422450190@qq.com | China | 10351 | 58 |
| Abmole Bioscience Inc. | 021-50967598 02150967598 |
sales@abmole.cn | China | 4495 | 58 |
| Bide Pharmatech Ltd. | 400-1647117 13681763483 |
product02@bidepharm.com | China | 62163 | 58 |
둘바루맙 관련 검색:
Follicle stimulating hormone
Secukinumab
Daratumumab
OMALIZUMAB
Dulaglutide
Trastuzumab emtansine
Ranibizumab
palivizumab
Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer
Eculizumab
Matuzumab
ticilimumab tremelimumab
CNTO 148
Aflibercept
abciximab
Avelumab
nimotuzumab
belimumab